Stock listing

Pharma Mar Sa

Selected listing: A2P9YT · LS · EUR · DE

Pharma Mar Sa (Lang & Schwarz: A2P9YT), Health Technology. Latest release Mar 13, 2026: Pharma Mar S A : Consolidated Financial Statements and Consolidated…

A2P9YT:LSEURDEUpdated October 2, 2026

Ticker: Lang & Schwarz: A2P9YT
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Other
Exchange: Lang & Schwarz
Currency: EUR

About Pharma Mar Sa

The company focuses on the development of innovative therapies for cancer treatment. Pharma Mar is dedicated to advancing its research and product pipeline to address unmet medical needs in oncology.

Latest news from Pharma Mar Sa

Pharma Mar S A : Consolidated Financial Statements and Consolidated Directors' Report (Consolidated Financial Statements and Consolidated Directors)

March 13, 2026

Pharma Mar S A : Press Release (PR PhM Results FY2025 final 1)

February 27, 2026

PharmaMar presents at ASCO that the Zepzelca®(lurbinectedin) and atezolizumab (Tecentriq®) combination significantly improves survival as first-line maintenance therapy for extensive-stage small cell lung cancer

June 3, 2025

Pharma Mar S A : Annual Report (ANNUAL REPORT 2024)

April 24, 2025

Pharma Mar S A : Separate Financial Statements (SEPARATE FINANCIAL STATEMENTS 2024)

April 24, 2025

All Pharma Mar Sa news →

Events

Replays

Pharma Mar, S.A. (0RC6) Q3 2023 Earnings Call
Fri, Oct 27, 2023 · 12:00 AM ET
Watch
Pharma Mar, S.A. (0RC6) Q4 2022 Earnings Call
Mon, May 01, 2023 · 12:00 AM ET
Watch

Research Pharma Mar Sa

Pharma Mar Sa company profile

View the public company page for Pharma Mar Sa on 6ix.

Pharma Mar Sa news

Read company news and market updates connected to Pharma Mar Sa.

Pharma Mar Sa investor events

Find investor webinars, events, and replay context for Pharma Mar Sa.